Eight patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2039. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2039
Next term end
7
Patent families
When these terms end
Each bar runs from grant to computed term end. 2021 to 2042.
US 11,192,900
Substituted 1,6-Dihydropyridinones and 1,2-Dihydroisoquinolinones as Bet Inhibitors
Oct 30, 2039
202520292033203720412042
7 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2041 · High confidence
Also notable
Ends Mar 2042 · High confidence
Also notable
Ends Jun 2041 · High confidence
Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds
US 11,826,430
The most cited patent in this portfolio, cited by 11 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2041.
Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds
US 11,834,458
Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2042.
Heterocyclic Compounds as Bet Inhibitors
US 11,584,756
Cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2041.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 28, 2027The maintenance fee for Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds (US 11,826,430) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds (US 11,834,458) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds (US 11,952,349) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds (2020) | 2 in force | to May 2041 |
| Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds (2022) | 1 in force | to Mar 2042 |
| Heterocyclic Compounds as Bet Inhibitors | 1 in force | to Jun 2041 |
| Substituted 1,6-Dihydropyridinones and 1,2-Dihydroisoquinolinones as Bet Inhibitors | 1 in force | to Oct 2039 |
| Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds (2022) | 1 in force | to May 2039 |
Patents held now
Soonest term end first.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,398,121 | Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds In force · High confidence | In force | High confidence | |
| US 11,192,900 | Substituted 1,6-Dihydropyridinones and 1,2-Dihydroisoquinolinones as Bet Inhibitors In force · High confidence | In force | High confidence | |
| US 12,208,141 | Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds In force · High confidence | In force | High confidence | |
| US 11,952,349 | Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds In force · High confidence | In force | High confidence | |
| US 11,826,430 | Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds In force · High confidence | In force | High confidence | |
| US 11,584,756 | Heterocyclic Compounds as Bet Inhibitors In force · High confidence | In force | High confidence | |
| US 11,834,458 | Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds In force · High confidence | In force | High confidence | |
| US 12,006,314 | Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 10 patents ended · 7 applications pending · 23 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.